Tezepelumab for treating severe asthma (TA880)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 April 2023
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) (TA834)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 October 2022
Dupilumab for treating severe asthma with type 2 inflammation (TA751)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 December 2021
Mepolizumab for treating severe eosinophilic asthma (TA671)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 February 2021
Benralizumab for treating severe eosinophilic asthma (TA565)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 3 September 2019Published: 6 March 2019
Reslizumab for treating severe eosinophilic asthma (TA479)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 October 2017
Omalizumab for treating severe persistent allergic asthma (TA278)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2013
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 12 February 2025
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TS ID 10085]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Budesonide–glycopyrronium–formoterol fumarate for treating severe asthma in people 12 years and over TS ID 12018Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC